New clinical trial to test monkeypox treatment – people living with HIV can participate
Monkeypox, a member of the smallpox family of viruses, has historically been rare outside west and central Africa. However, in May this year, an outbreak was identified in the UK, followed by cases appearing in multiple other countries outside Africa. On 23 July this year, the World Health Organization declared monkeypox to be a Public Health Emergency of International Concern. Although vaccines developed for smallpox may reduce the risk of catching monkeypox, there are currently no proven medication to speed recovery.
PLATINUM is a community-based trial, with participants taking the treatment or placebo in their own homes to test the efficacy and safety of tecovirimat (also known as TPOXX), an antiviral treatment originally developed for smallpox.
The trial is open to people living with HIV – if you are having mild symptoms of monkeypox and received a positive test result, ask your consultant to participate in trial.
Learn more about the study and enrolment information here: www.platinumtrial.org
Harun Tulunay, our Training and Volunteer Coordinator, tells his story of having monkeypox, and why he encourages other monkeypox patients to take part in the PLATINUM Trial.
“‘I don’t want anyone else to become as severely sick as I was, and this study will help patients who are not in hospital to understand how tecovirimat works, what they can expect, and the time frame of the recovery process. Knowing whether there is an effective treatment may also help to reduce any anxiety around monkeypox.”